Loading clinical trials...
Loading clinical trials...
A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)
Conditions
Interventions
cαStx1/cαStx2
Placebo
Locations
11
Argentina
Bahía Blanca, Argentina
Buenos Aires, Argentina
Córdoba, Argentina
La Plata, Argentina
Mendoza, Argentina
Paraná, Argentina
Start Date
November 1, 2010
Primary Completion Date
December 1, 2012
Completion Date
February 1, 2013
Last Updated
April 25, 2013
Lead Sponsor
Thallion Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions